3-[3-(trifluoromethyl)benzoyl]-1,3-bis(2-chloro-4-nitrophenyl)triazene | 1243357-81-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-[3-(trifluoromethyl)benzoyl]-1,3-bis(2-chloro-4-nitrophenyl)triazene
• 英文别名: N-(2-chloro-4-nitrophenyl)-N-[(2-chloro-4-nitrophenyl)diazenyl]-3-(trifluoromethyl)benzamide
• CAS: 1243357-81-4
• 化学式: C₂₀H₁₀Cl₂F₃N₅O₅
• 分子量: 528.231
• InChiKey: QEWREQPTTLITDK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.8
• 重原子数：
  35
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.05
• 拓扑面积：
  137
• 氢给体数：
  0
• 氢受体数：
  10

反应信息

• 作为产物：
  描述：

  1,3-bis(2-chloro-4-nitrophenyl)triazene 、 3-(三氟甲基)苯甲酰氯 在 三乙胺 作用下， 以 乙腈 为溶剂， 反应 0.5h， 以69%的产率得到3-[3-(trifluoromethyl)benzoyl]-1,3-bis(2-chloro-4-nitrophenyl)triazene
  参考文献：
  名称：

  Analogues Of 1,3-Bis(4-Nitrophenyl)Triazenes, Their Pharmaceutically Acceptable Salts And N-Acyl Derivatives For Tumour Treatment

  摘要：

  本发明涉及1,3-双(4-硝基苯基)三氮烯的类似物，其药用盐和N-酰基衍生物，用于治疗不同类型的肿瘤。这些化合物在非常低的浓度下显示细胞毒性（IC50为0.22至12.8μM），且具有良好的溶解性。这些化合物可用于单独或与其他细胞毒药物联合治疗肿瘤患者。

  公开号：

  US20110224412A1

文献信息

• [EN] ANALOGUES OF 1,3-BIS(4-NITROPHENYL)TRIAZENES, THEIR PHARMACEUTICALLY ACCEPTABLE SALTS AND N-ACYL DERIVATIVES FOR TUMOUR TREATMENT<br/>[FR] ANALOGUES DE 1,3-BIS(4-NITROPHÉNYL)TRIAZÈNES, LEURS SELS PHARMACEUTIQUEMENT ACCEPTABLES ET DÉRIVÉS N-ACYLÉS POUR UN TRAITEMENT ANTITUMORAL
  申请人：RUDJER BOSKOVIC INST

  公开号：WO2010103338A1

  公开（公告）日：2010-09-16

  The present invention refers to analogues of 1,3-bis(4-nitrophenyl)triazenes, their pharmaceutically acceptable salts and N-acyl derivatives for the treatment of different types of tumours. Said compounds show cytotoxicity at very low concentrations (IC50 0,22 to 12,8 μM), and good solubility. These compounds can be used in the treatment of tumour patients as single drugs or in combination with other cytostatics.

  本发明涉及1,3-双(4-硝基苯基)三氮烯的类似物，其药用盐和N-酰基衍生物，用于治疗不同类型的肿瘤。这些化合物在非常低的浓度下表现出细胞毒性（IC50为0.22至12.8μM），且具有良好的溶解性。这些化合物可用于单药治疗肿瘤患者，也可与其他细胞毒药物联合使用。
• Analogues Of 1,3-Bis(4-Nitrophenyl)Triazenes, Their Pharmaceutically Acceptable Salts And N-Acyl Derivatives For Tumour Treatment
  申请人：Osmak Maja

  公开号：US20110224412A1

  公开（公告）日：2011-09-15

  The present invention refers to analogues of 1,3-bis(4-nitrophenyl)triazenes, their pharmaceutically acceptable salts and N-acyl derivatives for the treatment of different types of tumours. Said compounds show cytotoxicity at very low concentrations (IC 50 0.22 to 12.8 μM), and good solubility. These compounds can be used in the treatment of tumour patients as single drugs or in combination with other cytostatics.

  本发明涉及1,3-双(4-硝基苯基)三氮烯的类似物，其药用盐和N-酰基衍生物，用于治疗不同类型的肿瘤。这些化合物在非常低的浓度下显示细胞毒性（IC50为0.22至12.8μM），且具有良好的溶解性。这些化合物可用于单独或与其他细胞毒药物联合治疗肿瘤患者。
• Diaryltriazenes as antibacterial agents against methicillin resistant Staphylococcus aureus (MRSA) and Mycobacterium smegmatis
  作者：Jure Vajs、Conor Proud、Anamaria Brozovic、Martin Gazvoda、Adrian Lloyd、David I. Roper、Maja Osmak、Janez Košmrlj、Christopher G. Dowson

  DOI：10.1016/j.ejmech.2016.12.060

  日期：2017.2

  Diaryltriazene derivatives were synthesized and evaluated for their antimicrobial properties. Initial experiments showed some of these compounds to have activity against both methicillin-resistant strains of Staphylococus aureus (MRSA) and Mycobacterium smegmatis, with MICs of 0.02 and 0.03 mu g/mL respectively. Those compounds with potent anti-staphylococcal and anti-mycobacterial activity were not found to act as growth inhibitors of mammalian cell lines or yeast. Furthermore, we demonstrated that one of the most active anti-MRSA diaryltriazene derivatives was subject to very low frequencies of resistance at <10(-9). Whole genome sequencing of resistant isolates identified mutations in the enzyme that lysylates phospholipids. This could result in the modification of phospholipid metabolism and consequently the characteristics of the staphylococcal cell membrane, ultimately modifying the sensitivity of these pathogens to triazene challenge. Our work has therefore extended the potential range of triazenes, which could yield novel antimicrobials with low levels of resistance. Crown Copyright (C) 2016 Published by Elsevier Masson SAS. All rights reserved.